Form 4: Poseida Therapeutics Executive Chairman Exercises and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Poseida Therapeutics' Executive Chairman, Mark J. Gergen, exercised stock options and sold shares on November 26, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Mark J. Gergen, the Executive Chairman of Poseida Therapeutics, exercised 30,000 stock options at a price of $2.781 per share on November 26, 2024.
- Concurrently, Mr. Gergen sold 30,000 shares of common stock at a price of $9.27 per share.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on June 21, 2024.
- Following these transactions, Mr. Gergen directly owns 651,291 shares of Poseida Therapeutics common stock and 126,372 employee stock options.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing related to insider transactions. It doesn't indicate any positive or negative sentiment about the company's performance.
Industry Context
This is a routine filing related to insider transactions. It is common for executives to use 10b5-1 plans to manage their stock holdings and avoid accusations of insider trading.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a standard practice among executives at publicly traded companies, including those in the biotechnology sector like Poseida Therapeutics.
- Similar filings are regularly seen from executives at companies such as Gilead Sciences, Amgen, and Biogen, reflecting routine stock transactions under pre-arranged plans.
- The prices at which the options were exercised and shares were sold are specific to Poseida's stock performance and are not directly comparable to other companies without further analysis of their respective stock valuations.
Stakeholder Impact
- The transactions may have a minor impact on the stock price, but are unlikely to significantly affect stakeholders due to the pre-planned nature of the trades.
Key Dates
| Date | Description |
|---|---|
| 06/21/2024 | Date the Rule 10b5-1 trading plan was adopted by Mark J. Gergen. |
| 11/26/2024 | Date of the stock option exercise and share sale. |
| 11/27/2024 | Date the Form 4 was signed. |
| 03/01/2028 | Expiration date of the employee stock options. |
Keywords
Poseida Therapeutics, Executive Chairman, Mark J. Gergen, stock options, share sale, Rule 10b5-1, insider trading, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.